Chicago— Researchers say they have shown that a new anticoagulant medicine could be considered for reducing stroke risk in patients with atrial fibrillation. If ultimately approved by the US Food and Drug Administration (FDA), the medication, rivaroxaban, would join newly approved dabigatran and standard-therapy warfarin as options for treating this population.
The optimism over rivaroxaban followed the researchers' presentation of results from the Stroke Prevention Using the Oral Direct Factor Xa Inhibitor Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation (ROCKET AF) trial during the Scientific Sessions of the American Heart Association (AHA) meeting held here in November. ROCKET AF is a noninferiority trial that found the new medication as effective as the standard treatment for preventing stroke and emboli in patients with atrial fibrillation.
Mitka M. New Alternative to Warfarin May Help Reduce Stroke Risk in Patients With AF. JAMA. 2011;305(1):25-26. doi:10.1001/jama.2010.1894